Tracking ctDNA for Pancreatic Cancer Before Surgery
Part of Cancer clinical trials.
This study looks at using a special blood test (ctDNA MRD) to track how well the tumor responds to chemotherapy before surgery for pancreatic cancer. It may help doctors decide if the treatment is working and guide next steps.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have pancreatic cancer that is either high-risk but removable, borderline removable, or locally advanced (not yet spread to distant organs).
- You are in good enough health to carry out daily activities on your own (ECOG 0 or 1).
- Your doctors expect you to live at least 6 months longer.
- You have not had any prior cancer treatment (like chemotherapy, radiation, or immunotherapy) for this disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three chemotherapy drugs given before surgery for pancreatic cancer that is removable or borderline removable. The goal is to shrink the tumor to make surgery more successful.
This trial tests whether using a special blood test (MRD) to guide chemotherapy after pancreatic cancer surgery can improve outcomes. It is for people who have had their cancer completely removed and are ready for standard follow-up therapy.
This study uses a special blood test to look for tiny amounts of cancer DNA after your pancreatic cancer surgery. It may help doctors see early if the cancer is coming back, so they can act sooner.
This study tests whether a blood test that looks at DNA changes (ctDNA methylation) can help predict how pancreatic cancer will behave and guide treatment decisions. It includes people with suspected pancreatic cancer who are planning surgery or a biopsy.
This trial studies a blood test that looks for tiny traces of cancer-related DNA (called ctDNA) in people with pancreatic cancer that can be removed with surgery. The goal is to see whether this test can better predict how the cancer behaves and guide treatment decisions around surgery.
This study looks at DNA signals from blood tests (so-called “ctDNA” and another type of DNA test) in people with early-stage pancreatic cancer. It aims to see whether these tests can help track cancer after surgery and check for signs of return.
Hear when a new Borderline Resectable Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.